Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy
Funds work combining imaging with liquid biopsy during cancer treatment, to see sooner whether it is working or resistance is emerging.
Two ways of watching a tumour respond to treatment exist and they are rarely used together. Imaging shows where and how big. A liquid biopsy — a fluid-based assay reading tumour material from blood — shows what is changing molecularly. Each misses what the other sees.
The National Cancer Institute funds integrating them during therapy in patients, to work out the optimal use of the two modalities…
Integration of imaging and fluid-based tumour monitoring, or liquid biopsy, assays during cancer therapy in patients, to determine the optimal use of both modalities in characterising therapy response and the emergence of resistance. Clinical trials are optional.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up